RxDoctor Payments Data

Mario Sabates, MD

Ophthalmology · Miami, FLNPI 1740330984

Payments from drug & device makers

$3,821in general payments, 2019–2025

Across 120 payments — averaging $31.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$963
  • AbbVie$734
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$398
  • Aerie Pharmaceuticals, Inc.$396
  • Glaukos Corporation$184
  • Biotissue Holdings Inc.$172
  • plus $972 from 13 others

What the payments were for

  • Food & beverage$3,821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,821 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$84,641
Medicare patients
239
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod138$43,787
LumiganBimatoprost120$36,544
CombiganBrimonidine Tartrate/Timolol84$30,628
Prednisolone Acetate551$25,152
Timolol Maleate401$19,935
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol108$11,428
Ketorolac Tromethamine229$9,328
RestasisCyclosporine11$9,260
RocklatanNetarsudil Mesylat/Latanoprost19$7,788
Latanoprost1,016$6,018
Ofloxacin289$5,822
Alphagan PBrimonidine Tartrate18$4,353
IlevroNepafenac11$4,119
Dorzolamide-TimololDorzolamide/Timolol/Pf39$4,114
SimbrinzaBrinzolamide/Brimonidine Tart20$4,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$734$80,784233 claims
Bausch & Lomb Americas Inc.Vyzulta$129$43,787138 claims
Aerie Pharmaceuticals, Inc.Rocklatan$396$7,78819 claims
NovartisIlevro$125$4,11911 claims
AlconSimbrinza$963$4,06620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →